Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Melanoma 4Pancreatic Neoplasms 2Colorectal Neoplasms 2Turcot syndrome 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1COVID-19 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × IMM-101 × Clear all
NCT06498518 2025-07-11

PRIMUS006

University of Glasgow

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04137822 2020-08-14

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Impatients N.V. trading as myTomorrows

No longer available
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡